{"id":81343,"date":"2026-06-02T12:05:15","date_gmt":"2026-06-02T12:05:15","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/"},"modified":"2026-06-02T12:05:15","modified_gmt":"2026-06-02T12:05:15","slug":"prokidney-appoints-kenneth-locke-as-chief-technical-officer","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/","title":{"rendered":"ProKidney Appoints Kenneth Locke as Chief Technical Officer"},"content":{"rendered":"<div>\n<p><em>Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel<\/em><\/p>\n<p>WINSTON-SALEM, N.C., June  02, 2026  (GLOBE NEWSWIRE) &#8212; ProKidney Corp. (Nasdaq: PROK) (\u201cProKidney\u201d or the \u201cCompany\u201d), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<\/p>\n<p>\u201cKen is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,\u201d said Bruce Culleton, M.D., CEO of ProKidney. \u201cAs we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.\u201d<\/p>\n<p>Mr. Locke joins ProKidney from Carisma Therapeutics, where he oversaw CMC, Quality and Regulatory functions and led technical strategy for first-in-human CAR Myeloid programs. He built and scaled teams to support clinical development and contributed to strategic asset transitions through licensing and technology transfer of cell and viral vector manufacturing processes.<\/p>\n<p>Previously, he held leadership roles at Celgene (now Bristol Myers Squibb), where he led external manufacturing and strategic sourcing for cell therapy programs, and at Novartis, where he helped advance early-stage cell therapy programs and established global capabilities across manufacturing and supply chain.<\/p>\n<p>\u201cThe opportunity to help advance a first-in-class autologous cell therapy for patients with severe chronic kidney disease is incredibly compelling,\u201d said Mr. Locke. \u201cProKidney has built a strong foundation with its in-house manufacturing capabilities and expertise in kidney disease, and I\u2019m energized to work with this talented team as we execute on our Phase 3 study and prepare for the next stage of growth.\u201d<\/p>\n<p>Mr. Locke began his career in research and procurement roles of increasing responsibility at Bristol Myers Squibb and other biopharmaceutical organizations. He holds a Master of Science in Molecular Biology from Lehigh University and a Bachelor of Science in Biology Education from Millersville University of Pennsylvania.<\/p>\n<p align=\"justify\"><strong>About ProKidney Corp.<\/strong><br \/>ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney\u2019s lead product candidate, rilparencel (also known as REACT<sup>\u00ae<\/sup>), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F-eKvnYe5UCzxL405ZBlumJZmliGhGq3RZm6JSPkO0jVPPjp_YlEK_CHaRD6B06ss2a8Stqz-cuEsRFDqS3Qxj1YA2IbxMOBLG5Mtay_Emko0YSZDNzFnPFcOxq4YV_5HkJCU569jxPIBD8-T33wWLTIS-Ju95r1L3Cq-GR-yVvdISmeeYjFhid5wMiN7a_owqLFEYpWQouFiXtBH2YnmlF5fFKMiGFjjqSm_HJ7lBvXylX6dhUgr5KnOZm9DPhkX2DN7_N0CT9KK0pYHAS18A==\" rel=\"nofollow\" target=\"_blank\" title=\"www.prokidney.com\">www.prokidney.com<\/a>.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p align=\"justify\">This press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. ProKidney\u2019s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the achievement and timing of the topline data readout of the Company\u2019s PROACT 1 trial and other milestones provided, the Company\u2019s beliefs that its Phase 3 REGEN-006 (PROACT 1) trial could be sufficient to support a potential BLA submission and full regulatory approval, eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company\u2019s expectation that current cash will support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company\u2019s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company\u2019s products, if approved, the advancement of the Company\u2019s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company\u2019s product candidates, and the advancement and funding of the Company\u2019s developmental programs, generally. Most of these factors are outside of the Company\u2019s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company\u2019s Class A common stock on Nasdaq; the inability of the Company\u2019s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company\u2019s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company\u2019s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company\u2019s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company\u2019s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company\u2019s financial performance; the Company\u2019s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company\u2019s business; and other risks and uncertainties included under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.<\/p>\n<p><strong>ProKidney Contact<\/strong><br \/>Ethan Holdaway<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kgkZWZRJr4PFj3x8jeFMHZ0wyyNOpHm4-Ts_Us99QIfFMhAvvLrsKuhg_OnN6IBV_G9lHuFz64NX4swn2DikduG4IBaclLYG3JcODl7t1Qex4B0mU8oiL8_6bt_UWbT4\" rel=\"nofollow\" target=\"_blank\" title=\"Ethan.Holdaway@prokidney.com\">Ethan.Holdaway@prokidney.com<\/a><\/u><\/p>\n<p><strong>Media Contact<\/strong><br \/>Audra Friis <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Wo3-elZQj-z52DiKsmbb0vWXcIR2BqfnkQUpR32v_uUddM0vFSc8nLhbjqVD6Hg2Sbk58P36wdK2WVCMDseZVp4UKt1gU3o5AxjqPKoTERc=\" rel=\"nofollow\" target=\"_blank\" title=\"audrafriis@sambrown.com\">audrafriis@sambrown.com<\/a><\/p>\n<p><strong>Investor Relations Contact<\/strong><br \/>Daniel Ferry<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AEpar_Xs3Qa0EhvtV9g4IQDPNYvWmshGvdR5FE1y_ScEwrzRIN2BBsFmsNxpql9e6Dm_R6QcgewfqGGK9Uk4Ww9nKZxRXRDRYPGJY0tODqiRdPmFnsZ5YHdZrwn-7vqh\" rel=\"nofollow\" target=\"_blank\" title=\"Daniel@lifesciadvisors.com\">Daniel@lifesciadvisors.com<\/a><\/u><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTU4YTAyYzEtNTQ2NC00NjljLWFhMTEtMjhiYmY2NzMzNTZjLTEyNTU4MjgtMjAyNi0wNi0wMi1lbg==\/tiny\/ProKidney.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) &#8212; ProKidney Corp. (Nasdaq: PROK) (\u201cProKidney\u201d or the \u201cCompany\u201d), a leading late clinical-stage cell therapy company [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-81343","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-people"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ProKidney Appoints Kenneth Locke as Chief Technical Officer - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ProKidney Appoints Kenneth Locke as Chief Technical Officer\" \/>\n<meta property=\"og:description\" content=\"Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Suppl\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T12:05:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1074\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"ProKidney Appoints Kenneth Locke as Chief Technical Officer\",\"datePublished\":\"2026-06-02T12:05:15+00:00\",\"dateModified\":\"2026-06-02T12:05:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/\"},\"wordCount\":1209,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"People\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/\",\"name\":\"ProKidney Appoints Kenneth Locke as Chief Technical Officer - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-06-02T12:05:15+00:00\",\"dateModified\":\"2026-06-02T12:05:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ProKidney Appoints Kenneth Locke as Chief Technical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ProKidney Appoints Kenneth Locke as Chief Technical Officer - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/","og_locale":"en_US","og_type":"article","og_title":"ProKidney Appoints Kenneth Locke as Chief Technical Officer","og_description":"Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Suppl","og_url":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-06-02T12:05:15+00:00","og_image":[{"width":1074,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"ProKidney Appoints Kenneth Locke as Chief Technical Officer","datePublished":"2026-06-02T12:05:15+00:00","dateModified":"2026-06-02T12:05:15+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/"},"wordCount":1209,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["People"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/","url":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/","name":"ProKidney Appoints Kenneth Locke as Chief Technical Officer - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-06-02T12:05:15+00:00","dateModified":"2026-06-02T12:05:15+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/prokidney-appoints-kenneth-locke-as-chief-technical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"ProKidney Appoints Kenneth Locke as Chief Technical Officer"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/81343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=81343"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/81343\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=81343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=81343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=81343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}